VTVT (vTv Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VTVT vTv Therapeutics Inc VTVT
28 GF Score
Price $35.56
View Full Analysis

What is vTv Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


vTv Therapeutics  (NAS:VTVT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


vTv Therapeutics Cyclically Adjusted PB Ratio Related Terms


vTv Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Cyclically Adjusted PB Ratio Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

vTv Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VTVT vs VXRT, ENGN, SPRB: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, vTv Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Cyclically Adjusted PB Ratio falls into.


VTVT
28GF Score
vTv Therapeutics Inc VTVT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

vTv Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, vTv Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.337/333.9520*333.9520
=6.337

Current CPI (Jun. 2026) = 333.9520.

vTv Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -459.669 241.428 -635.831
201612 -375.806 241.432 -519.820
201703 -510.202 243.801 -698.861
201706 -439.711 244.955 -599.467
201709 -563.236 246.819 -762.072
201712 -624.161 246.524 -845.515
201803 -612.296 249.554 -819.372
201806 -263.224 251.989 -348.841
201809 -111.619 252.439 -147.661
201812 -162.776 251.233 -216.370
201903 -84.780 254.202 -111.378
201906 -66.893 256.143 -87.213
201909 -53.216 256.759 -69.215
201912 -47.921 256.974 -62.276
202003 -55.346 258.115 -71.607
202006 -57.988 257.797 -75.118
202009 -41.800 260.280 -53.631
202012 -59.291 260.474 -76.017
202103 -39.107 264.877 -49.305
202106 -31.776 271.696 -39.057
202109 -12.963 274.310 -15.781
202112 -5.818 278.802 -6.969
202203 -4.835 287.504 -5.616
202206 -4.411 296.311 -4.971
202209 -8.134 296.808 -9.152
202212 -5.272 296.797 -5.932
202303 -9.422 301.836 -10.425
202306 -12.412 305.109 -13.585
202309 -12.387 307.789 -13.440
202312 -11.837 306.746 -12.887
202403 8.547 312.332 9.139
202406 6.771 314.175 7.197
202409 5.746 315.301 6.086
202412 4.670 315.605 4.941
202503 3.032 319.799 3.166
202506 1.055 322.561 1.092
202509 17.913 324.800 18.418
202512 16.359 324.054 16.859
202603 22.838 330.213 23.097
202606 6.337 333.952 6.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


vTv Therapeutics Business Description

Other Exchanges 5VT0:Germany
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
28GF Score

Get the complete analysis for VTVT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.56
Price